Pylarify pet radiopharmaceutical ordering period 3
Active Awarded Last action
- Contract number
- 36C24926N0218
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 9
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $962,610
Award facts
- Contract value 100% obligated
- $962,609.70 Current and potential, with all options
- Completion date 97% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lexington, KY 40502, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$3,622 | |
| Original award | $966,232 |
About this award
This contract award represents a call order under a Blanket Purchase Agreement (BPA) for PYLARIFY PET radiopharmaceutical, a diagnostic imaging agent used to detect and localize prostate cancer in positron emission tomography (PET) scans. Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., received this firm fixed-price order from Veterans Integrated Service Network 9 (VISN 9) on November 1, 2025, with a ceiling value of $962,609.70 and an ultimate completion date of October 31, 2026. The award carries no set-aside designation and falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Notably, the ordering period reflects a decreased quantity due to price increases, indicating market-driven adjustments to procurement volumes within the established ceiling.
This contract is part of Progenics Pharmaceuticals' broader portfolio of federal radiopharmaceutical supply agreements with the Veterans Health Administration and other federal healthcare agencies. The BPA structure enables VA medical centers and affiliated facilities within VISN 9 to efficiently issue task orders for critical medical imaging supplies that support oncology diagnostic programs. As a subsidiary of Lantheus Holdings, Inc., Progenics Pharmaceuticals maintains multiple significant IDVs with federal healthcare providers, including FSS contracts with ceiling values exceeding $290 million. The PYLARIFY supply chain ensures that VA facilities maintain access to specialized diagnostic agents necessary for prostate cancer screening and imaging procedures across the veteran healthcare network.
Quick answers
Who was awarded contract 36C24926N0218?
36C24926N0218 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 9 (Veterans Health Administration) on November 1, 2025.
How much is contract 36C24926N0218 worth?
The government has obligated $962,610 on 36C24926N0218.
Is contract 36C24926N0218 an order under another contract?
Yes. 36C24926N0218 is a BPA call under 36F79719D0170-36C24923A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24926N0218 competed?
The extent of competition for 36C24926N0218 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award